Clinical Trials Browser

Phase 2/3 × NETWORK × CCND1 Gene Amplification × Clear all

NCT02785939 2021-05-27

Lung-MAP: Palbociclib as Second-Line Therapy in Treating Cell Cycle Gene Alteration Positive Patients With Recurrent Stage IV Squamous Cell Lung Cancer

Phase 2/3 Completed

53 enrolled 15 charts

CCND1 Gene Amplification